
Advancing Holistic First-Line Care in Advanced Urothelial Carcinoma: Guideline-Based Strategies and Best Practices in Adverse Event Management
2026/1/13 | 23 mins.
Please visit answersincme.com/KEC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jonathan E. Rosenberg, MD and Dayna A. Leis, NP. In this activity, experts in genitourinary oncology management discuss evidence-based first-line approaches for advanced urothelial carcinoma (UC) and share practical strategies to recognize and manage adverse events (AEs) through coordinated, multidisciplinary care. Upon completion of this activity, participants should be better able to: Review guideline-recommended first-line systemic treatments for patients with advanced UC; Identify AEs among patients receiving preferred first-line systemic treatment for advanced UC; and Outline multidisciplinary strategies to optimize care for patients receiving preferred first-line systemic treatment for advanced UC.

Tina Q. Tan, MD - Infant RSV Protection: Guiding Families Through Immunization Decisions in Clinical Practice
2025/12/30 | 22 mins.
Please visit answersincme.com/WFH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in infectious diseases discusses RSV vaccination indications, scheduling, and uptake. Upon completion of this activity, participants should be better able to: Identify the pressing need for RSV prevention in infants (≤24 months); Compare the administration schedules and clinical indications of available RSV prophylactic agents for infants; and Review strategies to address caregiver concerns and increase uptake of RSV prophylaxis in infants.

Karen McAssey, BA, MD, M.Ed, FRCPC - Frail Bones, Strong Impact: Mending Gaps in Hypophosphatasia Recognition Across Canada
2025/12/24 | 21 mins.
Please visit answersincme.com/RND860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hypophosphatasia (HPP) discuss its multisystem burden and diagnostic challenges, and the importance of early referral for timely treatment. Upon completion of this activity, participants should be better able to: Describe the clinical burden and multisystem manifestations of HPP across the lifespan; Recognize key diagnostic challenges in HPP through practical screening strategies, including interpretation of alkaline phosphatase (ALP) and pyridoxal 5′-phosphate (PLP) levels; and Outline the importance of early referral and diagnostic confirmation to enable timely treatment initiation, including the role of genetic testing and family screening.

David R. Staskin, MD - Beyond Benign Prostatic Hyperplasia: Unmasking and Addressing Overactive Bladder in Men
2025/12/23 | 17 mins.
Please visit answersincme.com/FUA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in urology discusses overactive bladder in men with benign prostatic hyperplasia. Upon completion of this activity, participants should be better able to: Identify overactive bladder (OAB) in men who are being treated for benign prostatic hyperplasia (BPH); Review pharmacotherapy treatment expectations for treating OAB in men with BPH; and Formulate strategies to enhance treatment plans and support quality of life for men with OAB and BPH, including those with additional comorbidities.

Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care
2025/12/17 | 19 mins.
Please visit answersincme.com/NEH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.



CME in Minutes: Education in Primary Care